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Summary Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of
prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat
prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly
and was provisionally characterised as a tissue factor-factor VIla complex. There was no significant
differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels
in rats that developed tumours were significantly higher (P<0.01) than all other groups and there was a
positive correlation betwen tumour weight and PCA (r = 0.85, P<0.001). Furthermore, prostatic PCA levels
were higher (P< 0.01) in those tumours that had spread than in those which were organ confined. In five
animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and
levels were higher in the metastasis (P<0.02). We conclude that PCA reflects the malignant phenotype in this
model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential
tumour marker in the human disease.
One of the current difficulties in managing prostatic cancer is
the apparent variability in the natural history of localised
disease (Whitmore, 1990). Although it is now generally
accepted that, given time, most tumours will progress
(Johansson et al., 1989), a rational management policy for
organ-confined disease demands the identification of those
patients at high risk of significant disease progression. How-
ever, despite major advances in many areas of tumour
biology, there is presently no parameter which can accurately
provide this information (Whitmore, 1990).
Like other tumours, prostate cancer has been historically
associated with thromboembolic complications (Sac et al.,
1977) and a high incidence of occult coagulopathy (Adamson
et al., 1993). The association of cancer and coagulopathy is
well known (Trousseau, 1865), although the pathogenesis of
this interaction is multifactorial and incompletely under-
stood. Stimulated by the extensive evidence of implicating the
coagulation and fibrinolytic pathways in tumour growth and
spread, two main types of tumour-associated procoagulant
have been demonstrated (Francis, 1989). Cancer pro-
coagulant (CP) is a cysteine proteinase which appears to be
closely associated with the malignant state (Gordon et al.,
1975). This enzyme can activate factor X directly and occurs
in association with a variety of human tumours (Gordon et
al., 1979). More recently, an enzyme-linked immunoadsor-
bent assay for CP was described, and this preliminary study
demonstrated that CP may have a role as a tumour marker
(Gordon & Cross, 1990).
The other procoagulant that is associated with malignancy
is tissue factor (TF). This procoagulant differs from CP in
several important ways. For example, TF is a normal compo-
nent of the haemostatic system, initiating the extrinsic path-
way of blood coagulation by markedly enhancing the ability
of factor VII to cleave factor X (Brozna, 1990). TF is widely
distributed in the body, and some solid tumours, notably
ovarian, gastric and renal cell cancers, may express TF in
excess of their benign counterparts (Mussoni et al., 1986;
Zacharski et al., 1986; Szcsepanski et al., 1988). TF is not
normally produced by cells in contact with the blood. How-
ever, in some disease states, including cancer, TF may be
expressed by monocytes and endothelial cells, giving rise to
increased procoagulant activity in the blood (Edwards et al.,
1981) and urine (Carty et al., 1990) of patients with malig-
nant disease.
The current study was performed in an attempt to define
the natural history of tumour procoagulant activity in a
spontaneously metastasising model of autochthonous pros-
tate cancer. If a relationship between procoagulant activity
and tumour natural history was demonstrable, then further
investigation of this putative marker of biological potential
may be indicated.
Materials and methods
Animals, tumour induction and study design
The Lobund-Wistar (LW) rats used in this study were
derived from a colony that was randomly propagated
through 58 generations under germ-free conditions. Breeding
colonies obtained in this way were then conventionally reared
in isolated, air-conditioned rooms and further propagated.
Tumours were induced in 3-month-old LW rats as previously
described (Pollard & Luckert, 1986). Briefly, N-nitroso-N-
methylurea (MNU, Ash Stevens, Detroit, MI, USA, 30 mg
kg-') was injected into the lateral tail vein. One week later,
the animals received a subcutaneous implant containing
45 mg of testosterone propionate (TP; Sigma, St Louis, MO,
USA) under ether anaesthesia. The testosterone capsules
were renewed bimonthly on three occasions.
The carcinogenic programme was performed on 40 rats. At
monthly intervals, each rat was weighed, inspected for
disease and palpated abdominally for the presence of a pros-
tate tumour. At intervals between 6 and 11 months after
MNU administration, rats were sacrificed and underwent the
standard necroscopy procedure detailed below. Two control
groups, each comprising 10 rats, were run in parallel with the
study group. One control group received no MNU or tes-
tosterone, while the other received testosterone alone on a
bimonthly basis, i.e. similar to the study group. Five rats
from each control group were sacrificed at 6 months, the
other five at the completion of the study (11 months).
All animals underwent a standard necroscopy after being
weighed and sacrificed under ether. The abdomen and
thoracic cavities were opened longitudinally and the animals
exsanguinated by cardiac puncture. The peritoneal cavity and
thorax were examined closely for evidence of metastatic
disease and the bladder and prostate seminal vesicle complex
removed en bloc. A portion of any obvious tumour was then
removed and snap frozen in liquid nitrogen for subsequent
processing for procoagulant activity. In large tumours, care
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was taken to ensure that the portion sampled was peripheral
and therefore not necrotic. If there was no obvious tumour a
portion of the dorsal prostate was removed and snap frozen.
The bladder and prostate were then fixed in Bouin's solution
for 24 h and then transferred to 70% ethanol for histological
examination.
Extraction ofprocoagulant activity
Procoagulant activity was extracted from the prostatic tissue
by cryofragmentation. The frozen tissue was fragmented to a
fine powder using a Mikrodismembranator II (Braun
Biotech, Aylesbury, UK) and resuspended by 10-fold (w/v)
addition of assay buffer (Tris-HCl, pH 7.8). The sample was
then sealed and gently rotated at 4°C for 4 h before cent-
rifugation at 3,000g for 10 min. The supernatants were
transferred to individually coded microcentrifuge tubes and
stored at - 70°C until assayed.
Determination ofprocoagulant (factor X-activating) activity
Procoagulant activity was measured in a one-stage kinetic
assay performed in 96-well, flat-bottomed, microtitre plates.
Each well contained 40 jil of assay buffer (Tris-HCI;
pH 7.8), 20 jIl of calcium chloride (0.025 M), 20 jil of tissue
homogenate, 20 jil of human factor X (0.2 U ml-1; Sigma)
and 40I1 of factor Xa-specific chromogenic substrate (CBS
31:39; Diagnostica Stago, Asnieres, France). Each assay was
performed in duplicate and a blank in which factor X was
replaced by assay buffer was run in parallel for each sample.
The reagents were then incubated at 37°C and the rate of
cleavage of the chromogenic substrate was measured at
405 nm in Biokinetics EL 312e microplate reader.
For each example, the time interval over which the change
in absorbance was measured was adjusted to ensure that only
the initial (and linear) reaction rate was determined (i.e. when
the correlation coefficient of the curve most closely equalled
unity). The reaction rate of each sample was taken as the
mean of duplicate determinations corrected for the blank.
The procoagulant activity was corrected for protein concent-
ration measured with a commercially available Bradford dye-
binding assay (Bradford, 1976) (Pierce, Chester, UK). The
results were expressed as absorbance units per min per mg of
protein.
Characterisation ofrat prostate procoagulant activity
In order to characterise the rat prostate PCA, known
inhibitors of procoagulant activity were used. These were as
follows: a polyclonal antibody to human TF (a gift from
L.V.M. Rao, San Diego, CA, USA, 3% v/v); a monoclonal
antibody to human tissue factor (no. 4508, American Diag-
nostica, Greenwich, CT, USA); a monoclonal antibody to
human factor VII (American Diagnostica) the tissue factor
inhibitors concanavalin A [Sigma, 100 and 200 igml1' final
concentration (f.c.)] and phospholipase C (Sigma, 70,igmlm'
f.c.), the serine proteinase inhibitor diisopropyl fluorophos-
phate (DFP; Sigma; 1 mM) and the cysteine proteinase
inhibitor iodoacetamide (Sigma; 10 mM f.c.). Control pro-
coagulants comprised homogenates of LW rat lung (rat tissue
factor), recombinant human tissue factor (American Diag-
nostica), Russel's viper venom (serine proteinase; Diagnostica
Stago) and papain (cysteine proteinase; Sigma). Rat prostate
extracts or control procoagulant were incubated with and
without the various inhibitors, at the final concentrations
indicated, at 37°C for 30 min before assay of residual PCA as
described above.
Aluminium hydroxide binds to carboxyglutamic acid
residues and therefore adsorbs proteins such as the vitamin
K-dependent clotting factors II, VII, IX and X (Furie &
Furie, 1991). A 100 jil aliquot of prostate gland homogenate
was mixed with 10jl of 25% aluminium hydroxide gel
(BDH, Poole, UK) for 3min at 37°C and centrifuged at
3,000g for 10min (Denson, 1972). The procoagulant activity
of the supernatant was then determined as detailed above.
Statistical analysis
Data were not normally distributed so summary statistics are
described as medians and interquartile ranges. However, fur-
ther analysis of enzyme activities in relation to markers of
the malignant phenotype was performed using parametric
tests and summarised as means and standard deviations as
these subgroups of data were normally distributed.
Results
Over the study period none of the rats in the control groups
developed tumours. In the rats exposed to carcinogen, 16 of
the 40 rats had tumours at autopsy, nine of which had
metastasised. These were identified histologically as
moderately differentiated adenocarcinoma. In one animal,
extraprostatic spread could be neither confirmed nor refuted,
so a total of six rats were deemed to have non-metastatic
disease.
Procoagulant activity (PCA) was detected in all normal
and malignant prostate tissues tested. PCA (median, inter-
quartile range) was similar in the untreated control group
(2.89 units, 0.71-6.38), the TP-treated control group (1.53,
0.12-3.7) and the carcinogen-exposed group that had not
developed tumour (2.26, 041-2.96). As illustrated in Figure
1, however, PCA was significantly higher in those animals
with tumours (11.42, 5.85-39.56) when compared with all of
these groups (P<0.001). The PCA in the tumour group was
positively correlated with the wet weight of the tumour
(r = 0.85, P<0.001; Figure 2).
Levels of PCA in primary tumours (mean ± s.d.) were
significantly higher in those tumours which had spread
(31.2 ± 22.5) than in those that were localised (7.7 ± 4.6,
P<0.001). These data are presented in Figure 3a. In five
rats, secondary tumours were large enough to allow their
procoagulant activity to be compared with the primary. As
shown in Figure 3b, PCA activity in the metastases
(72.0 ± 17.0) was significantly higher than the parent
primaries (36.0 ± 18.0; P<0.02).
Rat prostate procoagulant activity was not inhibited by
either antibody to human tissue factor, concanavalin A or
iodoacetamide. However, PCA was significantly reduced by
incubation with the anti-VII antibody, by treatment with
DFP and phospholipase C and by adsorption on to
aluminium hydroxide. Appropriate reactivity of all inhibitors
was confirmed by control experiments with known pro-
coagulants (Table I). There was no qualitative difference
between the procoagulant activity detected in prostate
tumours and that found in normal rat prostate gland.
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Discussion
Stimulated by the association of cancer and thromboem-
bolism, O'Meara (1958) was the first to describe the throm-
boplastic properties of tumours. Since then procoagulant
activity has been described in a large number of human
tumours, including colonic, ovarian, renal cell and gastric
cancers (Mussoni et al., 1986; Zacharski et al., 1986;
Szczepanski et al., 1988). Similar studies have been conducted
with experimental cell lines, and in some the expression of
procoagulant activity (PCA) appears to reflect malignant
behaviour (Gilbert & Gordon, 1983). However, most of this
work has been in models that omit certain important parts of
the metastatic process. For example, lung seeding following
intravenous injection of tumour cells is not a good model of
metastasis. Clearly, if this property ofmalignant cells is to be
related to the human disease state it must be in a model that
duplicates all steps of the metastatic process. These criteria
are fulfilled by the model used in the present study.
Given the need for better predictors of tumour potential in
prostate cancer, this study was designed to determine the
natural history of PCA in a spontaneously metastasising
prostate cancer model (Pollard & Luckert, 1975). The main
problem with this model of prostate cancer is the need to
administer prolonged, non-physiological doses of testo-
sterone. This concern is even more pertinent in a study on
coagulation because of the possible procoagulant effect of
testosterone in the rat (Nakao et al., 1981). For these
reasons, an additional control group of rats receiving TP
alone was run in parallel with the untreated control and
carcinogen-exposed groups.
PCA was demonstrable in homogenates of both control
and tumour tissue. However, activity was significantly higher
in rats that developed prostate cancer. Notably, PCA was
not increased in the prostates of rats treated with tes-
tosterone alone or in animals exposed to the carcinogen but
which did not develop tumours. Further support for the
hypothesis that PCA is related to malignant transformation
comes from the observations that (1) PCA was correlated
with tumour size, (2) PCA in primary tumours was
significantly higher in animals with metastases and (3) PCA
in metastases was higher than that in primary tumours.
These findings suggest that PCA in the rat prostate parallels
aggressive tumour behaviour and that PCA is a feature of
aggressive cell lines. The fact that PCA in those rats exposed
to the carcinogens that did not develop tumours was similar
to controls suggests that this marker is normal in the
preneoplastic state and is only expressed abnormally in the
truly invasive state.
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Figure 3 a, Procoagulant activity (absorbance units min-' mg-'
protein, mean ± s.d.) of localised prostate tumours compared
with those that had spread. b, Comparison of procoagulant
activity in individual primary tumours and their corresponding
metastases.
Using methodology similar to that described here, the
PCA of human colorectal tumours was found to be higher
than normal control tissue (Francis et al., 1988), although
there was no relation between procoagulant activity and
histological dedifferentiation or pathological stage. Further
review of the literature does, however, find evidence to sup-
port our findings that PCA is a marker of aggressive
behaviour, although few studies have been in spontaneously
metastasising models such as reported here. Gilbert and Gor-
don (1983) demonstrated that the procoagulant activity of
B16 melanoma variants correlated with the degree of lung
metastasis after injection of tumour cells via the tail vein in a
murine model. These results were supported by studies ofPROCOAGULANT ACTIVITY IN RAT PROSTATE CANCER 289
Table I Characterisation of the rat prostate gland procoagulant activity
Rat prostate Rat lung rTF Papain RVV
Anti-TFa 5 7 93 ND ND
Anti-TFb 3 5 95 ND ND
Anti-FVII 58 38 0 ND ND
DFP 90 92 0 0 95
lodoacetamide 0 0 0 96 0
Con A (l00yigml ') 0 0 75 ND ND
Con A (200 igml-') 0 0 89 ND ND
PLC 75 78 88 ND ND
Aluminium hydroxide 94 80 - ND ND
aPolyclonal antibody (a gift from L.V.M. Rao). bMonoclonal antibody
(American Diagnostica no. 4508).
Abbreviations: TF, tissue factor; DFP, diisopropylfluorophosphate; con A,
concanavalin A; PLC, phospholipase C; rTF, recombinant human tissue factor;
RVV, Russel's viper venom; ND, not done.
Results are expressed as percentage inhibition of procoagulant activity and are
the mean of duplicate or triplicate experiments.
procoagulant levels in human melanoma (Donati et al.,
1986), in which the procoagulant activity of secondary
deposits was higher than that of primary tumours, although
only one metastasis had a matched primary tumour for
comparison. In both studies the procoagulant was reported
to be cancer procoagulant (Gordon et al., 1975).
Further work has suggested possible mechanisms by which
the expression of PCA may favour metastasis. Thus, pro-
coagulant activity may facilitate adherence to the
endothelium, extravasation of tumour cells or their prolifera-
tion at the site of a potential secondary deposit (Gasic, 1984).
The improved efficiency of metastatic seeding of clumps of
malignant cells compared with similar numbers of solitary
cells has been demonstrated (Liotta et al., 1976). The forma-
tion of such aggregates, whether they are between tumour
cells and fibrin or tumour cells and platelets, is facilitated by
expression of PCA and the subsequent generation of throm-
bin (Weiss, 1975). We have recently shown that cellular
procoagulant activity is directly related to tumour cell lodge-
ment via its ability to activate blood coagulation and form
tumour cell-platelet-fibrin thrombi (Amirkhosravi & Fran-
cis, 1993). Why these aggregates are more efficient in the
metastatic process remains to be conclusively demonstrated
but probably reflects their ability to persist at the site of
lodgement long enough for extravasation to occur (Amirk-
hosravi & Francis, 1993). PCA-mediated interaction with the
coagulation system may also explain the beneficial effects of
anticoagulant therapy in some tumour types (Amirkhosravi
& Francis, 1993; Zacharski & Meeham, 1993). This
hypothesis is supported by work with the PAIII rat prostate
model (Pollard & Luckert, 1975) showing that lung metas-
tasis from the extravascular implant site is reduced by war-
farin therapy (Neubauer et al., 1986).
The precise nature of the rat prostate procoagulant was
difficult to establish. Two antibodies to human tissue factor
(TF) failed to inhibit its activity, although this was probably
because of species differences (Kadish et al., 1983). However,
concanavalin (con) A also failed to block procoagulant
activity, and this finding is not readily explained. We have
previously failed to demonstrate con A inhibition in extracts
of human breast and colon tumours (J.L. Francis, unpub-
lished data), and others have reported that con A does not
inhibit the PCA of the rat MC28 fibrosarcoma (Pangasman
et al., 1992) even though the latter has most of the charac-
teristics of a tissue factor-factor VIIa complex. It is possible
that con A is a much less efficient inhibitor of tissue factor
once it is bound to factor VII (FVII) or that it becomes
bound to other, non-procoagulant proteins in crude tissue
extracts and therefore becomes unavailable to inhibit PCA.
The problems of characterising PCA in tissue extracts are
considerable and have recently been reviewed (Edwards et
al., 1993). In contast, rat prostate PCA was inhibited by
phospholipase C (PLC). This enzyme can inactivate tissue
factor and may also inhibit the activity of the TF-FVIIa
complex (Pusey & Mende, 1985). Further support for the
role of FVII in the rat prostate PCA comes from the finding
that its activity was adsorbed onto aluminium hydroxide gel.
This suggests the presence of gamma-carboxyglutamic acid
residues; a property of the vitamin K-dependent clotting
factors, including factor VII (Furie & Furie, 1991). This was
further supported by the partial inhibition with an antibody
to human factor VII. These are similar characteristics, apart
from the negative reaction with the human TF antibodies, to
those previously described for human breast and colon
cancer PCA (Francis et al., 1988; El-Baruni et al., 1990).
The lack of inhibition with iodoacetamide suggests that the
PCA is not cancer procoagulant (Gordon et al., 1975). In
contrast, PCA was blocked by DFP, which indicates the
presence of a serine active site. Although TF itself is not
inhibited by DFP, the PCA generated by complexing with
FVIIa is effectively blocked by this treatment (Wijngaards &
Immerzeel, 1977). In the last registry of animal tumour pro-
coagulants (Edwards et al., 1990) eight rat tumour pro-
coagulants were reviewed, of which four were adequately
characterised. All were thought to be TF. The 13762 Mat B
mammary adenocarcinoma PCA was a direct factor X
activator and may have been a TF-VIIa complex (Bade-
noch-Jones & Ramshaw, 1985). The MC28 rat fibrosarcoma
PCA also has the characteristics of a TF-VIIa complex
(Pangasnan et al., 1992; Amirkhosravi & Francis, 1993).
None of the tumour procoagulants studied in rats were
thought to be CP. Thus, the results described in other rat
tumour systems are consistent with those reported in the
present model.
Taken together, the characterisation tests suggest that the
rat prostate gland PCA measured in this study is most likely
a complex between tissue factor and factor VIla. We recog-
nise that the characterisation of this procoagulant is not
exhaustive, but until species-species antibodies to tissue fac-
tor and factor VII become available more accurate
identification will probably not be possible.
In summary, we have demonstrated an association between
procoagulant activity and several characteristics relevant to
tumour aggressiveness in a metastasising model of prostate
cancer. Caution must be exercised in extrapolating con-
clusions from animals to human disease. Nevertheless, given
the urgent need for accurate markers of biological potential
in human prostate cancer, a similar study seems warranted in
man.
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